Monoclonal SPINK1 antibodies have shown efficacy in preclinical models [8], suggesting that SPINK1 inhibition may prove a beneficial treatment strategy in the 15% of prostate cancers positive for SPINK1 overexpression. This evidence concerns the gene SPINK1 and prostate cancer.